Increased levels of circulating advanced glycation end-products in menopausal women with osteoporosis

International Journal of Medical Sciences

Volumn 11, Issue 4, 2014, Pages 453-460

  Yang, Deng Ho ^a,b   Chiang, Tsay I ^c,d   Chang, I Chang ^a,c   Lin, Fu Huang ^e   Wei, Cheng Chung ^a,c   Cheng, Ya Wen ^a,f  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d HUNGKUANG UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Advanced glycation end products; Biomarker; Osteopenia; Osteopontin; Osteoporosis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALKALINE PHOSPHATASE BONE ISOENZYME; COLLAGEN TYPE 1 CROSS LINKED TELOPEPTIDE; ESTROGEN; OSTEOPONTIN; TELOPEPTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RISK FACTOR; BLOOD; GENETICS; MENOPAUSE; METABOLIC BONE DISEASE; MIDDLE AGED; PATHOLOGY; POSTMENOPAUSE OSTEOPOROSIS; VERY ELDERLY; BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN BLOOD LEVEL; HIGH RISK POPULATION; LUMBAR SPINE; OSSIFICATION; OSTEOPENIA; PATHOPHYSIOLOGY; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DISEASES, METABOLIC; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MENOPAUSE; MIDDLE AGED; OSTEOPONTIN; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 84896456966     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8172     Document Type: Article

References (38)

1. Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet 2011;377:1276-87.
2. Organization WH. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. In: WHO, ed. Geneva, Switzerland; 1994.
3. Forwood MR, Vashishth D. Translational aspects of bone quality--vertebral fractures, cortical shell, microdamage and glycation: a tribute to Pierre D. Delmas. Osteoporos Int 2009;20 Suppl 3:S247-53.
4. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest 1997;99:457-68.
5. Verzijl N, DeGroot J, Oldehinkel E, et al. Age-related accumulation of Maillard reaction products in human articular cartilage collagen. Biochem J 2000;350(Pt 2):381-7.
6. Jakus V, Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res 2004;53:131-42.
7. Wautier JL, Schmidt AM. Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 2004;95:233-8.
8. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
9. Grillo MA, Colombatto S. Advanced glycation end-products (AGEs): involvement in aging and in neurodegenerative diseases. Amino Acids 2008;35:29-36.
10. Miyata T, Ishiguro N, Yasuda Y, et al. Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 1998;244:45-9.
11. Vytasek R, Sedova L, Vilim V. Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord 2010;11:83.
12. Odetti P, Rossi S, Monacelli F, et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci 2005;1043:710-7.
13. Sanguineti R, Storace D, Monacelli F, Federici A, Odetti P. Pentosidine effects on human osteoblasts in vitro. Ann N Y Acad Sci 2008;1126:166-72.
14. de Paula FJ, Horowitz MC, Rosen CJ. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev 2010;26:622-30.
15. Wongdee K, Charoenphandhu N. Osteoporosis in diabetes mellitus: Possible cellular and molecular mechanisms. World J Diabetes 2011;2:41-8.
16. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006;17:1514-23.
17. Saito M, Marumo K. Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 2010;21:195-214.
18. Duque G, Huang DC, Macoritto M, et al. Autocrine regulation of interferon gamma in mesenchymal stem cells plays a role in early osteoblastogenesis. Stem Cells 2009;27:550-8.
19. D'Amelio P, Roato I, D'Amico L, et al. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. Osteoporos Int 2011;22:2869-77.
20. D'Amelio P, Isaia GC. Immune System and Postmenopausal Bone Loss. Clinic Rev Bone Miner Metab 2009;7:262-8.
21. Weitzmann MN, Pacifici R. The role of T lymphocytes in bone metabolism. Immunol Rev 2005;208:154-68.
22. Nakashima T, Takayanagi H. Osteoclasts and the immune system. J Bone Miner Metab 2009;27:519-29.
23. Hung LF, Huang KY, Yang DH, Chang DM, Lai JH, Ho LJ. Advanced glycation end products induce T cell apoptosis: Involvement of oxidative stress, caspase and the mitochondrial pathway. Mech Ageing Dev 2010;131:682-91.
24. Lee SK, Kadono Y, Okada F, et al. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res 2006;21:1704-12.
25. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008;4:285-93.
26. Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis 2006;65:101-4.
27. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;8:260-70.
28. Ji JD, Woo JH, Choi SJ, Lee YH, Song GG. Advanced glycation end-products (AGEs): a novel therapeutic target for osteoporosis in patients with rheumatoid arthritis. Med Hypotheses 2009;73:201-2.
29. Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008;19:333-45.
30. Pedraza CE, Nikolcheva LG, Kaartinen MT, Barralet JE, McKee MD. Osteopontin functions as an opsonin and facilitates phagocytosis by macrophages of hydroxyapatite-coated microspheres: implications for bone wound healing. Bone 2008;43:708-16.
31. Kennedy OD, Brennan O, Rackard SM, et al. Effects of ovariectomy on bone turnover, porosity, and biomechanical properties in ovine compact bone 12 months postsurgery. J Orthop Res 2009;27:303-9.
32. Duque G, Huang DC, Dion N, et al. Interferon-gamma plays a role in bone formation in vivo and rescues osteoporosis in ovariectomized mice. J Bone Miner Res 2011;26:1472-83.
33. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 2010;21:1401-9.
34. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 2007;113:154-61.
35. Walker CG, Dangaria S, Ito Y, Luan X, Diekwisch TG. Osteopontin is required for unloading-induced osteoclast recruitment and modulation of RANKL expression during tooth drift-associated bone remodeling, but not for super- eruption. Bone 2010;47:1020-9.
36. Franke S, Ruster C, Pester J, Hofmann G, Oelzner P, Wolf G. Advanced glycation end products affect growth and function of osteoblasts. Clin Exp Rheumatol 2011;29:650-60.
37. Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol 2008;600:140-7.
38. Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int 2009;20:887-94.